RBC Capital Maintains Sector Perform on IGM Biosciences, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained a 'Sector Perform' rating on IGM Biosciences (NASDAQ:IGMS) but has reduced the price target from $11 to $8.
November 14, 2023 | 5:06 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
RBC Capital has maintained its 'Sector Perform' rating on IGM Biosciences but lowered the price target from $11 to $8, indicating a potential downside based on the analyst's expectations.
The reduction in price target by RBC Capital suggests that the analyst sees less upside potential for IGM Biosciences, which could lead to negative investor sentiment and a potential decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100